Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 - Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) announced plans on Tuesday to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027.The price reduction will affect the obesity injection Wegovy, its pill counterpart, the diabetes shot Ozempic, and the oral diabetes drug Rybelsus. The new list price for these medications will be $675 per month, a significant drop from their current prices, which range from $1,027 to $1,350 per month.According to Millar, out-of-pocket costs for commercially insured pati ...